Skip to main content
Fig. 9 | Cancer Nanotechnology

Fig. 9

From: A novel formulation of theranostic nanomedicine for targeting drug delivery to gastrointestinal tract cancer

Fig. 9

Biodistribution comparison of doxorubicin from GNP theranostic nanomedicine in liver, kidney, heart and tumour after IV and PO dose, at different time points. a Graph confirmed the reduction of doxorubicin in liver tissue with the passage of time. b Doxorubicin eliminated from the heart quickly. c Doxorubicin concentration was decreased with time and showed quick elimination from the body. d Oral administration showed most of the drug was bound to the target site, while after IV administration only a little amount was able to reach at the targeted site but that little amount was able to show effect until 48 h

Back to article page